- Home
- BKE vs CELC Comparison
BKE vs CELC Comparison
Compare BKE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | CELC |
|---|---|---|
| Founded | 1948 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 1992 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BKE | CELC |
|---|---|---|
| Price | $57.50 | $103.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $55.00 | ★ $100.13 |
| AVG Volume (30 Days) | 383.3K | ★ 955.3K |
| Earning Date | 11-21-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.82% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $1,277,894,000.00 | N/A |
| Revenue This Year | $8.24 | N/A |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | $13.99 | ★ N/A |
| Revenue Growth | ★ 4.67 | N/A |
| 52 Week Low | $33.12 | $7.58 |
| 52 Week High | $61.69 | $108.91 |
Technical Indicators
Market Signals| Indicator | BKE | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 72.30 |
| Support Level | $55.60 | $96.70 |
| Resistance Level | $57.80 | $108.91 |
| Average True Range (ATR) | 1.62 | 5.06 |
| MACD | 0.11 | -0.41 |
| Stochastic Oscillator | 86.14 | 69.60 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.